Oesophago-Gastric Cancer | ATTAX 2 (AG0603G EXT)
Phase II study of cetuximab (Erbitux™) plus weekly docetaxel chemotherapy in docetaxel refractory patients with EGFR positive advanced oesophago-gastric cancer.
Schema
.gif)
* Prior to submission to the reference laboratory of representative slides of the diagnostic tumour tissue for EGFR testing.
Summary
Most cases of oesophageal and gastric cancer are locally advanced or metastatic at presentation. Chemotherapy prolongs survival and improves quality of life in such patients, but standard chemotherapy for this disease has not been defined.
ATTAX 2 is an optional extension study for patients who have participated in the ATTAX study (AG0603) (all of whom receive docetaxel) and who have progressed either during or within six months of chemotherapy. The primary objective is to evaluate the response rate of cetuximab plus docetaxel in patients with docetaxel refractory advanced oesophago-gastric cancer. Secondary objectives include assessment of cetuximab plus docetaxel toxicity, progression free and overall survival, and improvements in symptom control.
